Clinical Guidelines

The National Strategy includes recommendations developed by the Task Force on Maternal Mental Health, a subcommittee of SAMHSA’s Advisory Committee for Women’s Services, to address the urgent public health crisis of maternal mental health and substance use issues.

This model standards guidance document, SAMHSA's National Model Standards for Peer Support Certification, is prepared in response to President Biden's 2022 Unity Agenda. This document outlines model standards for substance use disorder, mental health, and family/youth peer support certification.

This guideline provide evidence-based strategies and standards of care for the treatment of stimulant use disorders, stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use.

These guidelines provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.

This web page includes toolkits, guides, and webinars (including on-demand training courses) available from the MOC.

This issue brief makes implementation recommendations for low-barrier medication for opioid use disorders.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. It also focuses on the risks and harms of CBD and clarifies common misconceptions about CBD.

These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which assist women who are pregnant, or have recently had a child, and who use alcohol or drugs or who have a substance use disorder.

This guidance provides recommendations for screening pregnant patients for substance use disorder (SUD) to enhance the well-being of the maternalfetal dyad.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.